These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9398022)

  • 61. [Delayed recurrence of an endobiliary hepatocellular carcinoma without detectable intra-parenchymatous tumor].
    Vibert E; Chatelain D; Barrucand C; Garavito R; Yzet T; Delcenserie R; Mauvais F; Riboulot M; Capron JP; Dupas JL; Regimbeau JM
    Gastroenterol Clin Biol; 2006 May; 30(5):790-3. PubMed ID: 16801906
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Time to update radiological criteria for non-invasive diagnosis of hepatocellular carcinoma.
    Saini S; Pratt DS
    Hepatol Int; 2015 Jan; 9(1):1-2. PubMed ID: 25788371
    [No Abstract]   [Full Text] [Related]  

  • 63. Can hepatocellular carcinoma recurrence be prevented after liver transplantation?
    Kim JM
    Clin Mol Hepatol; 2021 Oct; 27(4):562-563. PubMed ID: 34551504
    [No Abstract]   [Full Text] [Related]  

  • 64. [Clinicopathological studies on patients with hepatocellular carcinoma. I. Selection of parameters for forecasting the prognosis (author's transl)].
    Nishioka M; Fukumoto Y; Kan D; Nawata J; Takemoto T; Fukuda T; Miyaji T
    Rinsho Byori; 1979 Jun; 27(6):515-8. PubMed ID: 224225
    [No Abstract]   [Full Text] [Related]  

  • 65. Amebic liver abscess: a diagnostic challenge.
    Dasrathy S; Sharma MP
    Trop Gastroenterol; 1995; 16(3):1-2. PubMed ID: 8838034
    [No Abstract]   [Full Text] [Related]  

  • 66. [Primary liver cell carcinoma].
    Wildhirt E
    Lebensversicher Med; 1987 Jan; 39(1):18-9. PubMed ID: 2882390
    [No Abstract]   [Full Text] [Related]  

  • 67. Liver transplantation: a simple inflammation marker predicts liver cancer prognosis.
    Tang ZY
    Nat Rev Gastroenterol Hepatol; 2011 Jul; 8(7):367-8. PubMed ID: 21725351
    [No Abstract]   [Full Text] [Related]  

  • 68. Why can't we cure primary liver cancer?
    Johnson PJ
    Eur J Cancer; 1995 Sep; 31A(10):1562-4. PubMed ID: 7488400
    [No Abstract]   [Full Text] [Related]  

  • 69. Predictive models for recurrence risk of hepatocellular carcinoma after liver transplantation: Still an unmet need.
    Piñero F; Carrihlo FJ; Silva MO
    Liver Int; 2017 May; 37(5):648-650. PubMed ID: 28453922
    [No Abstract]   [Full Text] [Related]  

  • 70. Prognostication in hepatocellular carcinoma: is it a burden or a ticket?
    Tsilimigras DI; Pawlik TM
    Br J Surg; 2021 Apr; 108(4):337-339. PubMed ID: 33734326
    [No Abstract]   [Full Text] [Related]  

  • 71. [Basic principles and medical responsibilities in tumor after-care].
    Ebeling K; Bodek B
    Z Arztl Fortbild (Jena); 1981 Jun; 75(11-12):534-40. PubMed ID: 6171108
    [No Abstract]   [Full Text] [Related]  

  • 72. Predicting Outcomes of Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma.
    Firl DJ; Sasaki K; Aucejo FN
    Gastroenterology; 2018 May; 154(6):1856-1857. PubMed ID: 29621517
    [No Abstract]   [Full Text] [Related]  

  • 73. [Transplantation strategies for hepatocellular carcinoma].
    Rauchfuß F; Settmacher U
    Chirurg; 2016 Oct; 87(10):890. PubMed ID: 27555057
    [No Abstract]   [Full Text] [Related]  

  • 74. Letter: mechanistic target of rapamycin inhibitors-do they impact on recurrence of hepatocellular carcinoma after liver transplantation?
    Cholongitas E
    Aliment Pharmacol Ther; 2019 Jul; 50(1):116-117. PubMed ID: 31184384
    [No Abstract]   [Full Text] [Related]  

  • 75. [Serological research in diagnosing hepatocellular carcinoma].
    Liu L; Yang DH; Tang SH
    Zhonghua Gan Zang Bing Za Zhi; 2008 Nov; 16(11):875-7. PubMed ID: 19032880
    [No Abstract]   [Full Text] [Related]  

  • 76. Mammalian Target of Rapamycin Inhibitors Against Hepatocellular Carcinoma Recurrence After Liver Transplantation.
    Cholongitas E
    Transplantation; 2016 Aug; 100(8):e43-4. PubMed ID: 27306530
    [No Abstract]   [Full Text] [Related]  

  • 77. Direct-acting antivirals and recurrence of hepatocellular carcinoma.
    Marrero JA; Singal AG
    Liver Transpl; 2017 Sep; 23(9):1099-1100. PubMed ID: 28722785
    [No Abstract]   [Full Text] [Related]  

  • 78. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis.
    ;
    J Hepatol; 2015 Jul; 63(1):237-64. PubMed ID: 25911335
    [No Abstract]   [Full Text] [Related]  

  • 79. Inflammation-based scores and hepatocellular carcinoma.
    Parisi I; O'Beirne J; Tsochatzis E
    Liver Transpl; 2014 Dec; 20(12):1529-30. PubMed ID: 25287417
    [No Abstract]   [Full Text] [Related]  

  • 80. Inflammation-based scores and hepatocellular carcinoma: "Faithful friends are hard to find".
    Lai Q; Lerut J
    Liver Transpl; 2014 Dec; 20(12):1527-8. PubMed ID: 25179960
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.